Does Biocare help with Stomach Paralysis?*
It’s been reported that patients taking a GLP-1 are 66% more likely to be diagnosed with gastroparesis.
Stomach (gastric) emptying is part of the digestive process wherein the foods and beverages we consume are moved from the stomach into the duodenum, the first part of the small intestine.
When contents are delayed in moving from the stomach to the small intestines, this is referred to as gastroparesis. While Biocare is not specifically designed to treat gastroparesis, its formulation aims to address some of the nutritional challenges and gastrointestinal side effects that individuals with gastroparesis may face, especially when using GLP-1 medications.
Please consult with your physician or healthcare provider before using Biocare if you have been diagnosed with gastroparesis.
High-Protein, Friendly Nutrition
Discover your favorite flavor with the Biocare 30G Protein Beverage Variety Pack! This 7-count pack includes a delicious mix of beverages — 2 Vanilla, 2 Chocolate, 2 Chocolate Salted Caramel, and 1 Strawberries & Cream — each packed with 30 grams of high-quality protein, essential vitamins, and anti-nausea ingredients. Specially designed for individuals on a GLP journey, these beverages help combat side effects while supporting weight management, muscle maintenance and overall wellness. Perfect for variety, convenience, and great taste — try Biocare’s protein beverage variety pack today!
• Wilding, John P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 10 Feb. 2021, www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Garvey, W. Timothy, et al. “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The Step 5 Trial.” Nature News, Nature Publishing Group, 10 Oct. 2022, www.nature.com/articles/s41591-022-02026-4
+ Wilding, John P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 10 Feb. 2021, www.nejm.org/doi/full/10.1056/NEJMoa2032183
++ Garvey, W. Timothy, et al. “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The Step 5 Trial.” Nature News, Nature Publishing Group, 10 Oct. 2022, www.nature.com/articles/s41591-022-02026-4
